Literature DB >> 14696436

Radiofrequency ablation in the treatment of pelvic recurrence of rectal cancer.

Antonio Nocchi Kalil1, Fábio Santarosa, Lenine Cunha, Plauto Beck, Felice Riccardi, José Vinícius Cruz, Jeferson Vinholes.   

Abstract

The aim was to assess the response to the treatment using thermal radiofrequency ablation in patients with pelvic recurrent rectal cancer. The location of the lesions as well as the placement of the percutaneous probe were guided by computed tomography. All ablations were performed with a RITA Medical Systems Starburst XL (nine-array, 5-cm) thermal ablation catheter and the Model 1500 generator (RITA Medical Systems, Inc.). The radiofrequency ablation treatment was performed in two patients with pelvic recurrent rectal cancer with poor response to chemoradiotherapy with no indication of new surgical treatment and suffering strong pain in the sacrum area. The serum carcinoembryonic antigen had a sharp reduction in a sixty-day period. The post-procedure tomography analysis showed the center of the tumor with necrosis and a ring of edema around it. Both patients had no complaints about the procedure, and they needed to take mild analgesics only on the first day right after the procedure for pain. In the follow-up one patient developed an abscess and needed to be readmitted but without recurrent pelvic pain. An effective response was shown by tumor necrosis and total relief of pain of the sacrum area.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696436

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Successful rectal cancer local recurrence radiofrequency ablation.

Authors:  C Bueno Muiño; J A García-Sáenz; E Santos Martín; J Sastre; J Mayol; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

2.  Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series.

Authors:  L G P H Vroomen; H J Scheffer; M C A M Melenhorst; N van Grieken; M P van den Tol; M R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-03       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.